AstraZeneca Pharma India Limited
Regd. Office :'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

Financial results for the quarter ended 30 June 2012

Part I

Rs in lakhs (except for number of shares)

Sl No.	Particulars	3 months ended 30/06/2012 (Unaudited)	3 months ended 31/03/2012 (Unaudited)	3 months ended 30/06/2011 (Unaudited)	Previous year ended 31/03/2012 (Audited)
1	**Income from operations**				
	a) Net sales/ income from operations (net of excise duty)	**9,126.08**	9,168.98	13,748.23	53,127.97
	b) Other operating income	**2.79**	9.70	6.04	24.05
	Total income from operations (net)	**9,128.87**	9,178.68	13,754.27	53,152.02
2	**Expenses**				
	(a) Cost of materials consumed	**715.85**	1,409.45	2,399.09	7,151.68
	(b) Purchase of stock-in-trade	**2,623.54**	834.28	3,148.44	11,923.13
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	**452.24**	2,216.16	(1,391.62)	(1,210.38)
	(d) Employee benefits expense	**3,339.55**	5,791.09	3,353.62	16,191.24
	(e) Depreciation and amortisation expense	**175.14**	181.03	172.74	733.86
	(f) Other expenses	**3,924.42**	3,843.76	3,727.46	16,070.05
	Total expenses	**11,230.74**	14,275.77	11,409.73	50,859.58
3	**Profit/ (loss) from operations before other income, finance costs and exceptional items (1-2)**	**(2,101.87)**	(5,097.09)	2,344.54	2,292.44
4	Other income	**783.53**	201.41	144.23	633.04
5	**Profit/ (loss) from ordinary activities before finance costs and exceptional items (3+4)**	**(1,318.34)**	(4,895.68)	2,488.77	2,925.48
6	Finance costs	**-**	-	-	-
7	**Profit/ (loss) from ordinary activities after finance costs but before exceptional items (5-6)**	**(1,318.34)**	(4,895.68)	2,488.77	2,925.48
8	Exceptional items	**-**	-	-	-
9	**Profit/ (loss) from ordinary activities before tax (7+8)**	**(1,318.34)**	(4,895.68)	2,488.77	2,925.48
10	Tax expense	**(503.74)**	(1,595.23)	813.95	948.97
11	**Net profit/(loss) from ordinary activities after tax (9-10)**	**(814.60)**	(3,300.45)	1,674.82	1,976.51
12	Extraordinary Item	**-**	-	-	-
13	**Net profit/(loss) for the period (11-12)**	**(814.60)**	(3,300.45)	1,674.82	1,976.51
14	**Paid-up equity share capital** (Face value of Rs 2 per equity share)	**500.00**	500.00	500.00	500.00
15	**Reserves excluding revaluation reserves as per the balance sheet of previous accounting year**				18,428.52
16	**Basic and diluted earnings (Rs) per share (not annualised)**	**(3.26)**	(13.20)	6.70	7.91
Part II					
A	**Particulars of shareholding**				
1	**Public shareholding**				
	- Number of shares	**2,500,050**	2,500,050	2,500,050	2,500,050
	- Percentage of shareholding	**10.0002%**	10.0002%	10.0002%	10.0002%
2	**Promoters and promoter group shareholding**				
	a) Pledged/Encumbered				
	- Number of shares	**-**	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	**-**	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	**-**	-	-	-
	b) Non-encumbered				
	- Number of shares	**22,499,950**	22,499,950	22,499,950	22,499,950
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	**100%**	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the Company)	**89.9998%**	89.9998%	89.9998%	89.9998%

B.	Particulars	3 months ended 30/06/2012
	Investor complaints	
	Pending at the beginning of the quarter	**Nil**
	Received during the quarter	**2**
	Disposed of during the quarter	**2**
	Remaining unresolved at the end of the quarter	**Nil**

Notes:

1. The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 10 August 2012.
2. Figures of the preceding 3 months ended 31 March 2012 are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. Also the figures upto the end of the third quarter were only reviewed and not subjected to audit.
3. The Company's sole reportable business segment is - 'Healthcare'. The other segments are not material and are hence disclosed as 'Others'. Others comprise service income pertaining to clinical trials and co-promotion activities.
4. Employee benefit expense for the quarter and year ended 31 March 2012 include provision for terminal compensation benefits payable under the voluntary retirement scheme amounting to Rs 1,877.18 lakhs.
5. Other income for the quarter ended 30 June 2012 includes an amount of Rs 693.49 lakhs towards compensation receivable for factory land acquired by National Highway Authority of India in the previous year.
6. The above statement of financial results has been reviewed by the statutory auditors. The statutory auditors have issued an unqualified review report. The review report has been filled with the stock exchange and is also available on the company's website.
7. A foreign national was appointed as Whole time Director of the Company during the previous year. The Company had filed an application with the Central Government under the Companies Act, 1956 seeking approval for the appointment of, and remuneration payable to, the said director in the previous year. The application is pending before the Central Government.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited

Anandh Balasundaram
Managing Director

Bangalore
Dated: **10 August 2012**

AstraZeneca Pharma India Limited
Regd. Office :'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

Segment wise revenue, results and capital employed

(Rs in lakhs)

Sl.no.	Particulars	3 months ended 30/06/2012 (Unaudited)	3 months ended 31/03/2012 (Unaudited)	3 months ended 30/06/2011 (Unaudited)	Previous year ended 31/03/2012 (Audited)
1	**Segment revenue**				
	(a) Healthcare	8,327.42	8,303.82	12,947.86	49,977.92
	(b) Others	801.45	874.86	806.41	3,174.10
	Total	9,128.87	9,178.68	13,754.27	53,152.02
	Less: Inter-segment revenue	-	-	-	-
	Net income from operations	9,128.87	9,178.68	13,754.27	53,152.02
2	**Segment results**				
	Profit/(loss) before tax and interest				
	(a) Healthcare	(2,078.25)	(5,122.57)	2,317.06	2,165.28
	(b) Others	(23.62)	25.48	27.48	127.16
	Total	(2,101.87)	(5,097.09)	2,344.54	2,292.44
	Add: Other income	783.53	201.41	144.23	633.04
	Less: Interest	-	-	-	
	Total profit/(loss) before tax	(1,318.34)	(4,895.68)	2,488.77	2,925.48
3	**Capital employed**				
	(a) Healthcare	13,056.25	11,722.25	15,240.58	11,722.25
	(b) Others	619.21	817.67	637.20	817.67
	(c) Unallocated	4,438.47	6,388.60	3,766.00	6,388.60
	Total	18,113.93	18,928.52	19,643.78	18,928.52

Notes :

1 Certain assets and liabilities of the Healthcare segment are interchangeably used for other segments for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.

2 Figures of the preceding 3 months ended 31 March 2012 are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. Also the figures upto the end of the third quarter were only reviewed and not subjected to audit.